U.S. Competition Watchdog Decries Drug Deals

Law360, New York (January 17, 2007, 12:00 AM EST) -- As Congress hears arguments on so-called authorized generics, a new report by the Federal Trade Commission reveals what the antitrust watchdog calls a worrisome rise in cozy deals between generic and brand drug makers.

While the head of the world’s largest generic pharmaceutical manufacturers testified Wednesday before a senate committee in defense of rival company agreements, the Federal Trade Commission said the deals cheated consumers out of billions of dollars in savings on cheap drugs.

A study released Wednesday by the FTC shows the number of...
To view the full article, register now.